These cytoskeletal genes (MYH9, PLEC, ITGB1) and mesenchymal markers (VIM, ACTN4), were previously reported by our lab to be up-regulated with cisplatin resistance development and involved in phenotypic and morphological modulation observed in our neuroblastoma cell model (Piskareva et al., 2015). This evidence concerns the gene PLEC and neuroblastoma.